The increasing demand for radiopharmaceuticals in Asia Pacific region is backed by improving healthcare infrastructure along with an increasing number of healthcare facilities, rising prevalence of chronic disorders and active role played by the government organization in controlling radiopharmaceuticals.
The dependency on nuclear reactors is observed to be reducing, as the hospital-based cyclotron facilities are emerging. As a result, novel isotopes of Thallium, Fluorine and Rubidium are gaining popularity. Additionally, emerging applications such as in brain disorders using technetium are key trends witnessed in the marketplace.
Regulatory agencies play critical role in the ethical movement of these products. For instance, in India, the Department of Atomic Energy (DAE) is responsible for development of nuclear technology and its applications in medical (i.e., nuclear medicine), agriculture and basic research.
Southeast Asia region is anticipated to grow at a healthy rate. Major countries in this region are dependent on the nuclear reactor-based production of isotopes. For instance, the BATAN reactor in Indonesia is the key producer of isotopes for the country. Moreover, the neighboring nations such as Malaysia, Korea, Singapore, China and Bangladesh are the key customer for this plant.
In-depth report on Asia Pacific radiopharmaceuticals market by Grand View Research: